XTL Biopharmaceuticals Ltd. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
XTLB Nasdaq 2836 www.xtlbio.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for XTL Biopharmaceuticals Ltd.

XTL Announces Receipt of Staff Delist Determination from Nasdaq - May 22nd, 2026 2:10 pm
XTL Biopharmaceuticals to Acquire Psyga Bio, Establishing a Leading Psychedelic Biotechnology Platform with Advanced Clinical Pipeline, Licensed GMP Manufacturing and Proprietary Psilocybin Technologies - Apr 29th, 2026 6:58 am
XTL Biopharmaceuticals Announces ADS Ratio Change - Mar 20th, 2026 2:10 pm
XTL Announces Receipt of Staff Delist Determination from Nasdaq and Plans to Request Hearing - Feb 27th, 2026 2:30 pm
XTL Update on Recent Developments - Jan 29th, 2026 2:05 pm
XTL Announces Receipt of Nasdaq Notification Regarding Minimum Stockholders’ Equity Deficiency - Jan 23rd, 2026 2:10 pm
Top Midday Gainers - Jan 13th, 2026 11:54 am
XTL Biopharmaceuticals Acquires 85% of NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership - Jan 13th, 2026 7:28 am
XTL Biopharmaceuticals Acquires 85% of Beyond Air’s Subsidiary NeuroNOS, Entering the Massive Autism Market with Nobel Prize-Winning Scientific Leadership - Jan 13th, 2026 5:30 am
XTL Announces Receipt of Nasdaq Notification Letter Regarding Minimum Bid Price Deficiency - Dec 24th, 2025 2:00 pm